Epigenetic aberrations contribute to prostate cancer carcinogenesis and disease progression.
Efforts have been made to target DNA methyltransferase and histone deacetylases (HDACs) in prostate cancer and other solid tumors but have not had the success that was seen in the hematologic malignancies. Oral, less toxic, and more specific agents are being developed in solid tumors including prostate cancer. Combinations of epigenetic agents alone or with a targeted agent such as androgen receptor signaling inhibitors are promising approaches and will be discussed further.
Written by:
Lin J, Wang C, Kelly WK. Are you the author?
Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Reference: Semin Oncol. 2013 Jun;40(3):393-401.
doi: 10.1053/j.seminoncol.2013.04.010
PubMed Abstract
PMID: 23806502
